RET融合基因定义了一种独特的非小细胞肺癌分子及临床病理学亚型.docx

然后，一起守着古朴的时光，迎接每一天的黎明。弱水三千，只取一瓢饮，不褪色，不黯淡，任凭尘世的风摇曳着冬日的风雪，我始终是你最美的红颜，你是我最美的时光。 然后，一起守着古朴的时光，迎接每一天的黎明。弱水三千，只取一瓢饮，不褪色，不黯淡，任凭尘世的风摇曳着冬日的风雪，我始终是你最美的红颜，你是我最美的时光。 RET Fusi ons Define a Unique Molecular and Cli ni copathologic Subtype of Non -Small Cell Lung Cancer Abstract Purpose The RET fusi on gene has bee n rece ntly described in a subset of non -small cell lung cancers (NSCLCs). Because we have limited knowledge about these tumors, this study was aimed at determining the clinicopathologic characteristics of patients with NSCLC harboring the RET fusion gene. Patients and Methods We examined the RET fusion gene in 936 patients with surgically resected NSCLC using a reverse tran scriptase polymerase cha in react ion (PCR) plus qua ntitative real-time PCR strategy, with validati on using immun ohistochemical and fluoresce nt in situ hybridizati on assays. A subset of 633 lung adenocarcinomas was also studied for EGFR, KRAS, HER2, and BRAF mutations, as well as ALK rearrangements. Patient characteristics, including age, sex, smoking history, stage, grade, International Association for the Study of Lung Can cer/America n Thoracic Society/Europea n Respiratory Society classificati on of subtypes of lung ade no carci no ma, and relapse-free survival, were collected. Results Of 936 patie nts with NSCLC, the RET fusi on ge ne was exclusively detected in 13 patients (11 of 633 patients with adenocarcinomas and two of 24 patients with ade no squamous cell carci no mas). Of the 13 patie nts, nine patie nts had KIF5B-RET, three patie nts had CCDC6-RET, and one patie nt had a novel NCOA4-RET fusio n. Patie nts with lung ade no carci no mas with RET fusi on gene had more poorly differe ntiated tumors (63.6%; P = .029 for RET v ALK, P = .007 for RET v EGFR), with a tendency to be youn ger ( 60 years; 72.7%) and n ever-smokers (81.8%) and to have solid subtype (63.6%) and a smaller tumor ( 3 cm) with N2 disease (54.4%). The media n relapse-free survival was 20.9 mon ths. Con clusi on